Loading...

Audentes Therapeutics

DB:22A
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
22A
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
  • Audentes Therapeutics has significant price volatility in the past 3 months.
22A Share Price and Events
7 Day Returns
-4.7%
DB:22A
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
10.7%
DB:22A
-10.2%
DE Biotechs
-6%
DE Market
22A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Audentes Therapeutics (22A) -4.7% 2% 55.7% 10.7% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 22A outperformed the Biotechs industry which returned -10.2% over the past year.
  • 22A outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
22A
Industry
5yr Volatility vs Market
Related Companies

22A Value

 Is Audentes Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Audentes Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Audentes Therapeutics.

DB:22A Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:22A
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:22A using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Audentes Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:22A DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -136.68 Analyst x1 -126.58
2020 -165.61 Analyst x2 -142.05
2021 -61.82 Analyst x2 -49.11
2022 162.20 Analyst x2 119.33
2023 167.34 Analyst x2 114.02
2024 197.96 Est @ 18.29% 124.91
2025 223.44 Est @ 12.87% 130.58
2026 243.73 Est @ 9.08% 131.92
2027 259.39 Est @ 6.42% 130.02
2028 271.24 Est @ 4.57% 125.92
Present value of next 10 years cash flows $558.96
DB:22A DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $271.24 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$3,508.81
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,508.81 ÷ (1 + 7.98%)10
$1,628.91
DB:22A Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $558.96 + $1,628.91
$2,187.87
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,187.87 / 43.59
$50.19
DB:22A Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:22A represents 0.88034x of NasdaqGM:BOLD
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88034x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 50.19 x 0.88034
€44.18
Value per share (EUR) From above. €44.18
Current discount Discount to share price of €34.25
= -1 x (€34.25 - €44.18) / €44.18
22.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Audentes Therapeutics is available for.
Intrinsic value
22%
Share price is €34.25 vs Future cash flow value of €44.18
Current Discount Checks
For Audentes Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Audentes Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Audentes Therapeutics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Audentes Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Audentes Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:22A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.40
NasdaqGM:BOLD Share Price ** NasdaqGM (2019-04-18) in USD $38.9
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Audentes Therapeutics.

DB:22A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:BOLD Share Price ÷ EPS (both in USD)

= 38.9 ÷ -3.40

-11.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Audentes Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Audentes Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Audentes Therapeutics's expected growth come at a high price?
Raw Data
DB:22A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.43x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
44.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Audentes Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Audentes Therapeutics's assets?
Raw Data
DB:22A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $10.17
NasdaqGM:BOLD Share Price * NasdaqGM (2019-04-18) in USD $38.9
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:22A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:BOLD Share Price ÷ Book Value per Share (both in USD)

= 38.9 ÷ 10.17

3.83x

* Primary Listing of Audentes Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Audentes Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Audentes Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Audentes Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

22A Future Performance

 How is Audentes Therapeutics expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
44.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Audentes Therapeutics expected to grow at an attractive rate?
  • Audentes Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Audentes Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Audentes Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:22A Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:22A Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 44.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:22A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:22A Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 505 88 263 7
2022-12-31 353 -62 77 8
2021-12-31 137 -126 -92 9
2020-12-31 12 -129 -172 11
2019-12-31 0 -128 -164 12
DB:22A Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -108 -129
2018-09-30 -103 -118
2018-06-30 -94 -106
2018-03-31 -87 -98
2017-12-31 -85 -90
2017-09-30 -73 -86
2017-06-30 -56 -76
2017-03-31 -58 -67
2016-12-31 -49 -60
2016-09-30 -49 -50
2016-06-30 -49 -42
2016-03-31 -36 -33

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Audentes Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Audentes Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:22A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Audentes Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:22A Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.80 12.16 -0.33 7.00
2022-12-31 1.71 8.27 -3.08 8.00
2021-12-31 -1.80 2.88 -4.21 9.00
2020-12-31 -3.66 -2.51 -4.21 12.00
2019-12-31 -3.78 -3.29 -4.46 13.00
DB:22A Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.40
2018-09-30 -3.39
2018-06-30 -3.28
2018-03-31 -3.28
2017-12-31 -3.40
2017-09-30 -3.48
2017-06-30 -3.52
2017-03-31 -4.32
2016-12-31 -5.59
2016-09-30 -8.72
2016-06-30 -21.61
2016-03-31 -21.40

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Audentes Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Audentes Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Audentes Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

22A Past Performance

  How has Audentes Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Audentes Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Audentes Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Audentes Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Audentes Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Audentes Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Audentes Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:22A Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -128.82 30.00 106.67
2018-09-30 -117.60 25.83 100.05
2018-06-30 -106.32 22.35 91.02
2018-03-31 -97.69 20.14 83.32
2017-12-31 -90.24 17.28 75.64
2017-09-30 -85.54 15.30 70.86
2017-06-30 -75.90 13.90 62.41
2017-03-31 -67.32 12.30 55.35
2016-12-31 -59.67 11.28 48.67
2016-09-30 -49.95 9.78 39.64
2016-06-30 -41.61 8.54 32.52
2016-03-31 -32.87 7.64 24.84
2015-12-31 -26.46 6.09 20.10
2015-09-30 -20.64 4.88 16.00
2015-06-30 -16.07 3.53 12.89
2015-03-31 -12.77 2.36 10.65
2014-12-31 -10.82 1.67 9.28
2013-12-31 -3.05 1.14 1.91

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Audentes Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Audentes Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Audentes Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Audentes Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Audentes Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

22A Health

 How is Audentes Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Audentes Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Audentes Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Audentes Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Audentes Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Audentes Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Audentes Therapeutics Company Filings, last reported 3 months ago.

DB:22A Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 442.75 0.00 414.31
2018-09-30 310.56 0.00 280.69
2018-06-30 340.96 0.00 314.43
2018-03-31 352.44 0.00 326.13
2017-12-31 156.60 0.00 133.61
2017-09-30 175.32 0.00 156.05
2017-06-30 162.05 0.00 145.01
2017-03-31 102.53 0.00 81.73
2016-12-31 119.37 0.00 104.88
2016-09-30 138.36 0.00 119.18
2016-06-30 77.88 0.00 55.26
2016-03-31 91.64 0.00 80.27
2015-12-31 101.69 0.00 95.23
2015-09-30 48.01 0.14 41.11
2015-06-30 50.71 0.00 50.38
2015-03-31 59.86 0.00 60.45
2014-12-31 59.86 0.00 60.45
2013-12-31 12.91 0.00 12.95
  • Audentes Therapeutics has no debt.
  • Audentes Therapeutics had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Audentes Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Audentes Therapeutics has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 35.5% each year.
X
Financial health checks
We assess Audentes Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Audentes Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

22A Dividends

 What is Audentes Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Audentes Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Audentes Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Audentes Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Audentes Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:22A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:22A Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Audentes Therapeutics has not reported any payouts.
  • Unable to verify if Audentes Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Audentes Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Audentes Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Audentes Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Audentes Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Audentes Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Audentes Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

22A Management

 What is the CEO of Audentes Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Matt Patterson
COMPENSATION $6,927,180
AGE 46
TENURE AS CEO 6.4 years
CEO Bio

Mr. Matthew R. Patterson, also known as Matt, has been the Chairman of Audentes Therapeutics Inc., since November 5, 2018 and has been its Director since November 2012. Mr. Patterson co-founded Audentes Therapeutics, Inc. in November 2012 and is its Chief Executive Officer since November 2012 and was its President from November 2012 to May 2018. He is also intimately involved in Audentes' day-to-day operations. Mr. Patterson has more than 20 years of experience in the research, development and commercialization of innovative treatments for rare diseases and has held positions of senior management in both private and public biotechnology companies. He was an Entrepreneur-In-Residence with OrbiMed Advisors LLC from November 2011 to December 2012. Prior to OrbiMed, from December 2004 to August 2011, Mr. Patterson worked for Amicus Therapeutics, Inc. He served as the President of Amicus Therapeutics, Inc. from February 18, 2011 to September 2011. He served as an Acting Chief Executive Officer of Amicus Therapeutics, Inc. from April 2011 to August 31, 2011. He served as the Chief Operating Officer of Amicus Therapeutics Inc. since September 2006. He is a commissioned officer in the Navy Reserve. He served as the Chief Business Officer of Amicus Therapeutics Inc. from December 2004 to September 2006. He served as Vice President of Commercial Planning and Government Affairs at BioMarin Pharmaceutical Inc. since July 2003 and served as its Vice President of Regulatory and Government Affairs from Director of Regulatory Affairs in January 2002. He joined BioMarin Pharmaceutical Inc. in August 1998. He served as Regulatory Affairs Manager of BioMarin Pharmaceutical Inc. from August 1998 to July 1999 and its Director of Regulatory Affairs from July 1999 to January 2002. At BioMarin Pharmaceutical Inc. where he oversaw the development of Aldurazyme® (laronidase) for the treatment of MPS I and initiated the Sales and Marketing functions for genetic diseases. He worked for Genzyme Corporation from December 1993 to May 1995 and then Regulatory Affairs from May 1995 to July 1998, where he contributed to the development and global licensing of multiple biotechnology products. He has been Vice Chairman and Director at Alliance for Regenerative Medicine since August 11, 2016. He has been Member of Executive Committee of Alliance for Regenerative Medicine since 2018. He has been a Director of Homology Medicines, Inc. since January 17, 2018. He has expertise in the fields of business, biotechnology and drug development. Mr. Patterson is a Member of the board of directors of Gilda’s Club of New York City. Mr. Patterson holds a B.A. in Biochemistry from Bowdoin College.

CEO Compensation
  • Matt's compensation has increased whilst company is loss making.
  • Matt's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Audentes Therapeutics management team in years:

3.9
Average Tenure
51
Average Age
  • The tenure for the Audentes Therapeutics management team is about average.
Management Team

Matt Patterson

TITLE
Co-Founder
COMPENSATION
$7M
AGE
46
TENURE
6.4 yrs

Natalie Holles

TITLE
President & COO
COMPENSATION
$4M
AGE
45
TENURE
0.9 yrs

Tom Soloway

TITLE
Executive VP & CFO
COMPENSATION
$3M
AGE
51
TENURE
3.6 yrs

John Gray

TITLE
Senior VP & Chief Scientific Officer
COMPENSATION
$768K
AGE
55
TENURE
1.9 yrs

Andrew Chang

TITLE
Director of Investor Relations

Mark Meltz

TITLE
Senior VP & General Counsel
TENURE
0.1 yrs

Sarah Spencer

TITLE
Vice President of Corporate Communications

David Nagler

TITLE
Senior VP of Human Resources & Corporate Affairs
AGE
66
TENURE
4.2 yrs

Suyash Prasad

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$715K
AGE
48
TENURE
5.2 yrs

Mary Newman

TITLE
Senior Vice President of Regulatory Affairs
AGE
59
TENURE
4.5 yrs
Board of Directors Tenure

Average tenure and age of the Audentes Therapeutics board of directors in years:

3.1
Average Tenure
60
Average Age
  • The tenure for the Audentes Therapeutics board of directors is about average.
Board of Directors

Matt Patterson

TITLE
Co-Founder
COMPENSATION
$7M
AGE
46
TENURE
0.4 yrs

Lou Lange

TITLE
Lead Independent Director
COMPENSATION
$187K
AGE
69
TENURE
0.4 yrs

Scott Morrison

TITLE
Independent Director
COMPENSATION
$202K
AGE
60
TENURE
3.3 yrs

Tom Schuetz

TITLE
Independent Director
COMPENSATION
$195K
AGE
57
TENURE
5.8 yrs

Alan Beggs

TITLE
Member of Scientific & Clinical Advisory Board

Deborah Bilder

TITLE
Member of Scientific & Clinical Advisory Board
TENURE
3.1 yrs

Alan Boyd

TITLE
Member of Scientific & Clinical Advisory Board
AGE
63
TENURE
3.1 yrs

Kevin Flanigan

TITLE
Member of Scientific & Clinical Advisory Board
TENURE
3.1 yrs

Mike Lawlor

TITLE
Member of Scientific & Clinical Advisory Board
TENURE
3.1 yrs

Benedikt Schoser

TITLE
Member of Scientific & Clinical Advisory Board
TENURE
3.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
16. Nov 18 Sell Louis Lange Individual 15. Nov 18 15. Nov 18 -24,000 €19.88 €-477,094
X
Management checks
We assess Audentes Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Audentes Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

22A News

Simply Wall St News

22A Company Info

Description

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Details
Name: Audentes Therapeutics, Inc.
22A
Exchange: DB
Founded: 2012
$1,507,901,405
43,593,716
Website: http://www.audentestx.com
Address: Audentes Therapeutics, Inc.
600 California Street,
17th Floor,
San Francisco,
California, 94108,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM BOLD Common Stock Nasdaq Global Market US USD 20. Jul 2016
DB 22A Common Stock Deutsche Boerse AG DE EUR 20. Jul 2016
Number of employees
Current staff
Staff numbers
207
Audentes Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:54
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.